Information Provided By:
Fly News Breaks for August 1, 2017
ICPT
Aug 1, 2017 | 07:13 EDT
Cantor Fitzgerald analyst Elemer Piros raised his price target for Intercept Pharmaceuticals to $69 citing "meaningful" Ocaliva revenue growth following the company's Q2 results. The analyst maintains an Underweight rating on the shares, which closed yesterday down $17.90 to $117.13. The analyst says that while the occurrence of a patient death in the LTSE portion of CONTROL study raises some concerns on safety, he remains focused on the 750-patient interim analysis of Phase 3 REGENERATE in NASH due in the first half of 2019.
News For ICPT From the Last 2 Days
There are no results for your query ICPT